Zenosense, Inc. (ZENO) Posts Test Results, Now Trading on OTCQB Venture Market

• Second round of testing for MIDS Cardiac™ detection technology for cardiac emergency triage reveals breakthrough quantitative testing results
• American Heart Association projects that 130 million adults in the U.S. will have some form of cardiovascular disease by 2035, with total costs expected to reach $1.1 trillion
• Studies performed outside the United States have demonstrated that high-sensitivity troponin testing speeds the triage of patients with suspected acute myocardial infarction (AMI, “Heart Attack”)
• Identifying low levels of troponin using a rapid-response, handheld diagnostic device for cardiac emergency triage can speed the treatment of AMI and improve treatment outcomes
• Identifying a low-risk patient could permit early emergency room discharge and avoid unnecessary hospitalization and costs

Health care technology company Zenosense, Inc. (OTCQB: ZENO) has completed two important milestones recently. The first was a successful second round of quantitative testing for the MIDS detection technology; the technology is core to the development of MIDS Cardiac™, a handheld device to rapidly test for certain cardiac biomarkers at the point of care. The second milestone relates to the company’s uplisting to the OTC Markets Group OTCQB Venture Market. By trading on the OTCQB Venture Market, Zenosense is better positioned to build shareholder value with a goal of enhancing liquidity and achieving fair valuation (http://ibn.fm/4q5BI).

Zenosense recently released breakthrough quantitative test results on the patented MIDS detection technology, which is being developing through its joint ownership in MIDS Medical Limited (“MML”), based at the prestigious Sci-Tech Daresbury campus in the United Kingdom. Targeting a major unmet medical need, MIDS Cardiac™ is being designed for use in emergency settings to help medical staff rapidly diagnose heart attack at an early stage and improve treatment and patient outcomes.

In a news release announcing the quantitative testing results (http://ibn.fm/jrS3f), Zenosense reported that the revised and improved sensor electronics detection system of its MIDS technology confirmed the testing results announced in late 2017 with materially improved results of a near doubling of sensitivity in detecting commercially available assay beads. The MIDS Cardiac™ device will utilize the MIDS technology, or ‘Magnetic Immunoassay Detection System’, which is capable of detecting extremely low levels of magnetic field disturbance caused by discrete test particles, the company states.

“MIDS is a hugely challenging development,” MML Managing Director and Chief Scientific Officer Dr. Nasser Djennati said in announcing the test results. “The results of this second round of testing are quite extraordinary, as magnetic detection at this level for this application is unheard of. We can now move forward and apply the MIDS detection to established assay techniques used in conventional analyzers as we seek to deliver state-of-the-art laboratory standard, high sensitivity cardiac troponin testing at the Point of Care.”

Every year about 735,000 Americans experience a heart attack, according to the Centers for Disease Control and Prevention (http://ibn.fm/Ig78O). Heart disease, the leading cause of death for both men and women, kills about one in every four people, according to the CDC. In fact, more than seven million Americans will go to the emergency room with chest pain symptoms this year, but 90 percent of these patients will not have an acute myocardial infarction (a heart attack) and no major adverse cardiac event will occur with the next 30 days, the American Medical Association reported in the February 2018 JAMA journal (http://ibn.fm/Zn9Wk).

These patients, however, are commonly hospitalized or kept under observation for an evaluation that often results in a diagnosis that does not include a heart attack. Being able to identify those patients who are at low-risk for a heart attack may permit early emergency room discharge and avoid unnecessary hospitalization. Rapid turnaround of low-risk patients could mean shorter wait times, increased satisfaction, improved outcomes and cost-saving benefits, as the article notes.

In its 2018 update on heart disease and stroke statistics (http://ibn.fm/FcSEa), the American Heart Association again reiterates that coronary heart disease (43.8 percent) is the leading cause of deaths attributable to cardiovascular disease (CVD) in the U.S., followed by stroke (16.8 percent), high blood pressure (9.4 percent), heart failure (9.0 percent) and other cardiovascular diseases (17.9 percent). By 2035, some 130 million adults in the U.S., or 45 percent of the population, are projected to have some form of CVD. Total costs related to CVD are expected to reach $1.1 trillion.

Successfully achieving detection equal or superior to state of the art laboratory analyzers with advanced portability allowing it to be used at point of care, including in an emergency setting, could make MIDS Cardiac™ an absolute game changer that could help save lives and money by enabling a swift diagnosis with a previously unheard of accuracy at the point of care (http://ibn.fm/mTVLw), the company states.

“These (test) results should not be underestimated,” Carlos Gil, CEO of Zenosense, stated in a news release. “I am not aware of any other detection technology suitable for use at the Point of Care which comes anywhere close to achieving these results. We are now so far within the limit of detection I am extremely confident that high sensitivity rapid troponin testing can become a reality in emergency settings. Achieving these results is a huge step towards that. I truly believe we have a blockbuster technology in the making.”

For more information, visit the company’s website at www.Zenosense.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php